Form PTC	D/SB/08/	Α			P.	
INFORMATION DISCLOSURE			Application Number	Not Yet Assigned	<u> </u>	
			Filing Date	Herewith		
STATE	MENT	BY APPI	LICANT	First Named Inventor	Éric DUPONT et al.	N.E.
			,	Group Art Unit	Not Yet Assigned	25
(use a	s many s	sheets as n	ecessary)	Examiner Name	Not Yet Assigned	86
Sheet	1	of	6	Attorney Docket Number	014985-6U1	19.

xr Initials	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of
. )	Number	Kind Code (if known)		Cited Document MM-YYYY
7 <b>W</b>	Re: 28093		Balassa	07-1974
a	3,478,146		Balassa	11-1969
	3,966,908		Balassa	06-1976
	4,042,457		Kuettner et al.	08-1977
	4,212,857		Balassa et al.	07-1980
	4,243,582		Spilburg et al.	01-1981
	4,350,682		Balassa	09-1982
	4,356,261		Kuettner	10-1982
	4,444,752		Prudden	04-1984
	4,456,589		Holman et al.	06-1984
	4,469,676		Hecmati	09-1984
	4,473,551		Schinitsky	09-1984
1	4,656,137		Balassa	04-1987
	4,746,729		Kuettner et al.	05-1988
M/	4,749,522		Kamarei	06-1988

			FOREIGN PATE	NT DOCUMENTS		
		Foreign Patent Docume	ent		Date of	T <sub>1</sub>
Exr Initials	Country Code	Number	Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Publication of Cited Document MM-YYYY	
AMW.	PCT	9309766			05-1993	
	PCT	9412510			06-1994	
	PCT	9503036			02-1995	
	PCT	9532722			12-1995	
	PCT	9623512			08-1996	
	PCT	9716197			05-1997	
1	JP	60-178820			09-1985	
1	JP	59-039828			03-1984	
1 <i>4</i> ***	JP	45-001444			01-1970	
Ü						

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T <sub>1</sub>
M	OIKAWA, T., et al., "A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis." <i>Cancer Letters</i> , 51 (1990) 181-186.	
	MOSES, M., et al., "Inhibitors of Angiogenesis," Biotech 1991; 9; pp. 630-634.	
- 1	FOLKMAN, J., et al., "Angiogenic Factors," Science, Vol. 235, pp. 442-446.	
SAN	LUER, C.A., "Inhibitors of Angiogenesis from Shark Cartilage," Fed. Proc. 45(4):949.	

Examiner Signature ////Z	Date Considered 9/2	22/03
	/	

Form PT	O/SB/08	A		Complete if Known			
	INFORMATION DISCLOSURE			Application Number	Not Yet Assigned		
				Filing Date	Herewith		
STATE	STATEMENT BY APPLICANT			First Named Inventor	Éric DUPONT et al.		
<b>l</b> , .	(use as many sheets as necessary)			Group Art Unit	Not Yet Assigned		
(use a			ecessary)	Examiner Name	Not Yet Assigned		
Sheet	2	of	6	Attorney Docket Number	014985-6U1		

		U.S	S. PATENT DOCUMENTS	
Exr Initials	U.S. Patent Document Number	Kind Code (if	Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document
h/		known)		MM-YYYY
Ago	4,822,607		Balassa et al.	04-1989
7V	5,075,112		Lane	12-1991
	5,096,892		Folkman et al.	03-1992
	5,135,919		Folkman et al.	08-1992
	5,583,153	1	Brahn	12-1996
	5,618,925	1	Dupont et al.	04-1997
	5,843,920		Weisz	12-1998
	5,985,839		Dupont et al.	11-1999
	6,025,334		Dupont et al.	02-2000
h. 1	6,028,118		Dupont et al.	02-2000
	6,168,807		Dupont et al.	01-2001

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book,	Τı
Initials	magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book,	
	, also include publisher and city and/or county where published.	
A. A	SUZUKI, et al., "Cartilage-derived Antitumor Factor (CATF): A High Molecular Weight Fraction	
<b>d</b> / M.(	Cartilage Extract Inhibits Solid Tumor Growth," Journal of Bone and Mineral Metabolism, 1984	
17 W	Vol. 2, No. 3, pp. 53-57.	
17/	LANGER, R., et al., "Isolation of a Cartilage Factor That Inhibits Tumor Neovascularization,"	
V	Science, Vol. 193, pp. 70-72.	
	SORGENTE, N., et al., "The Resistance of Certain Tissues to Invasion," Laboratory	
	Investigation, Vol. 32, No. 2, 1975, pp. 217-222.	
	BREM, H., et al., "Inhibition of Tumor Angiogenesis Mediated by Cartilage," The Journal of	
	Experimental Medicine, Vol. 141, 1975, pp. 427-439.	
	KUETTNER, K., et al., "Tumor Cell Collagenase and Its Inhibition by a Cartilage-Derived	
	Protease Inhibitor," Science, Vol. 196, pp. 653-654.	
	WEINGARTEN, M., et al., "Synthetic Substrates of Vertebrate Collagenase," Biochemistry 24,	
	6730-6734 (1985).	
	SADOVE, A., et al., "Inhibition of Mammary Carcinoma Invasiveness with Cartilage-Derived	
	Inhibitor," Orthopaedic Surgery, pp. 499-501.	
	PAULL, B., et al., "Regulation of Tumor Invasion by Cartilage-Derived Anti-Invasion Factor in	
	Vitro," <i>JNCI</i> , Vol. 67, No. 1, pp. 65-73 (1981).	
	MORALES, T., et al., "Characterization of the Metalloproteinase Inhibitor Produced by Bovine	
	Articular Chondrocyte Cultures," Biochimic et Biophysica Acta, 760, pp. 221-229 (1983).	
	MOSES, M., et al., "Identification of an Inhibitor of Neovascularization from Cartilage," Science,	
	Vol. 248, pp. 1408-1410.	
	MOSES, M., et al., "A Metalloproteinase Inhibitor as an Inhibitor of Neovascularization," Journal	
M40	of Cellular Biochemistry, Vol. 47, pp. 230-235 (1991).	
<del></del>		<del></del>

Examiner Signature	MITE	Date Considered	9/22/03
			7

Form PT	O/SB/08B			Complete if Known		
				Application Number	Not Yet Assigned	
	MATION			Filing Date	Herewith	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Éric DUPONT et al.	
				Group Art Unit	Not Yet Assigned	
(use a	s many sh	eets as ne	ecessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	6	Attorney Docket Number	014985-6U1	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book,	T <sub>1</sub>
Initials	magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	
This	MOSES, M., "A Cartilage-Derived Inhibitor of Neovascularization and Metalloproteinases,"	
HIM	Clinical and Experimental Rheumatology 11 (Supp. 8), pp. S67-S69 (1993).	
<del>    9   -                               </del>	MOSES, M., et al., "Metalloproteinase Inhibition as a Mechanism for the Inhibition of	
	Angiogenesis," Angiogenesis: Key Principles-Science-Technology-Medicine, pp. 146-151	
l i	(1992).	
<del> </del>	McGUIRE, T., et al., "Antiproliferative Activity of Shark Cartilage With and Without Tumor	-
1 1	Necrosis Factor-α in Human Umbilica Vein Endothelium," <i>Pharmacotherapy</i> , 1996;16(2), p.	
	237.	
<del>                                     </del>	LEE, A., et al., "Shark Cartilage Contains Inhibitors of Tumor Angiogenesis," Science, Vol. 221,	
1 1	pp. 1186-1187.	
<del>   </del>	MEDINA, "Mammary Tumorigenesis in Chemical Carcinogen-Treated Mice. VI. Tumor-	
l i	Producing Capabilities of Mammary Dysplasias in BALB/cCrgl Mice," <i>J. Natl. Cancer Inst.</i> , Vol.	
	57, No. 5, pp. 1185-1189.  DAVIS, P., et al., "Inhibition of Angiogenesis by Oral Ingestion of Powdered Shark Cartilage in	
	a Rat Model," <i>Microvascular Research</i> , Vol. 54, pp. 178-182 (1997).	
	MATHEWS, J., "Media Feeds Frenzy Over Shark Cartilage as Cancer Treatment," <i>Journal of</i>	
<u> </u>	the National Cancer Institute, Vol. 85, No. 15, p. 1190 (1993).	
	SCOTT, et al., "Selective Demineralization of Hard Tissues in Organic Solvents: Retention or	
	Extraction of Proteoglycan?", J. Microsc., 134(3), pp. 291-291.	
	PAVIA, et al., "Introduction to Organic Laboratory Techniques a Contemporary Approach," 2nd	
<b></b>	Ed., Saunders College Publishing, Philadelphia, pp. 500-501.	
	BURDICK, et al., "High Purity Solvent Guide," 2nd Ed., Burdick & Johnson Laboratories, Inc., pp. 128-137.	
<del></del>	SHEU, et al., "Effect of U-995, a Potent Shark Cartilage-Derived Angiogenesis Inhibitor, an	-
	Anti-Angiogenesis and Anti-Tumor Activities," Abtucabcer Researcg, 18L, 4435-4442 (1998).	
<del></del>	ARNETT, F., <i>et al.</i> , Arthritis & Rheumatism, 31(3):315-324 (1988).	
<del> </del>	CHABOT-FLETCHER, M., et al., "Interleukin-8 Production is Regulated by Protein Kinase C in	
I \	Human Keratinocytes," <i>The Journal of Investigative Dermatology</i> , 103(4): 509-515 (1994).	
	ELIAS, P.M., "Epidermal Lipids, Barrier Fnction, and Desquamation," <i>J. Invest. Dermatol.</i>	
	80:044s-049s (1993).	
	GROVE, G.L., "Age-Related Differences in Healing of Superficial Skin Wounds in Humans" in	
	The effects of aging in oral mucosa and skin. ed. Squier & Hill CRC Press, pp. 121-127.	
	MATSUI, M.S., et al., "Protein Kinase C in Normal Human Epidermal Keratinocytes During	
	Proliferation and Calcium-Induced Differenciation," <i>J. Invest. Dermatol.</i> 99:565-571 (1992).	
	MEDINA, D., et al., "Response of Hyperplastic Aveolar Nodule Outgrowth-Line D1 to Mammary	
	Tumor Virus, Nodule-Inducing Virus, and Prolonged ", <i>J. Natl. Cancer Inst.</i> 42:303-310	
	(1969).	
1	NICKOLOFF, B.J., et al., "Aberrant Production of Interleukin-8 and Trombospondin-1 Psoriastic	
$\setminus$	Keratinocytes Mediates Angiogenesis," Am. J. Pathology 144(4):820-828 (1994).	
211	ORESAJO, C., et al., "Eye Area Problems Puffiness, Bags, Dark Circles and Crowsfeet,"	
1 1/W	Cosmetics and Toiletries 102:29-34 (1987).	

Examiner Signature	Date Considered 9/22	103
		/

Form PT	O/SB/08B			Complete if Known		
				Application Number	Not Yet Assigned	
	MATION			Filing Date	Herewith	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Éric DUPONT et al.	
		4		Group Art Unit	Not Yet Assigned	
(use a	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	Sheet 4 of 6			Attorney Docket Number	014985-6U1	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr	,	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book,	T <sub>1</sub>
Initials	s \	magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a	
	<del>,    </del>	book, also include publisher and city and/or county where published.	
	W	PINNAGODA, "Guidelines for transepidermal water loss (TEWL) measurement," Contact	
1 / 4	100	Dermatitis 22:164-178 (1990).	
I/J		RITCHIE, et al., "Clinical Studies with an Articular Index for the Assessment of Joint	
		Tenderness in Patients with Rheumatoid Arthritis," Quarterly Journal of Medicine, New Series	
		XXXVII, No. 147, pp. 393-407 (1968).	
1 1		BLOOD, C. H., et al., "Tumor interactions with the vasculature: angiogenesis and tumor	
1 /		metastasis," Biochimica et Biophysica Acta, 1032:89-118 (1990).	
		BREM, S., "Angiogenesis and Cancer Control: From Concept to Therapeutic Trial," JMCC,	
1 /		6(5):436-458 (1999).	
		DAVIS-SMYTH, T., et al., "The second immunoglubulin-like domain of the VEGF tyrosine	
1 1		kinase receptor FIt-1 determines ligand binding and may initiate a signal transduction	
		cascade," The EMBO Journal 15:18, 4919-4927 (1996).	
		DUPONT, E., et al., "Antiangiogenic Propoerties of a Novel Shark Cartilage Extract: Potential	
1		Role in the Treatment of Psoriasis," Journal of Cutaneious Medicine and Surgery, 2:3, 146-152	
		(1998).	
		DVORAK, H.F., et al., "Vascular Permeability Factor/Vascular Endothelial Growth Factor and	
		the Significance of Microvascular Hyperpermeability in Angiogenesis," pp. 98-132.	
		FAN, T., "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting	<del>                                     </del>
		of gene therapy," <i>Angiogenesis Review</i> , 16, 57-66 (1995).	
		GRIFFIOEN, A., et al., "Angiogenesis: Potentials for Pharmacologic Intervention in the	
		Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation," <i>Pharmacological</i>	
		Reviews, 52:2, 237-268 (2000).	
		HANAHAN, D., et al., "Patterns and Emerging Mechanisms of the Angiogenic Switch during	
		Tumorigenesis," <i>Cell</i> , 86:353-364 (1996).	
		JACKSON, J. R., et al., "The codependence of angiogenesis and chronic inflammation,"	
		FASEB J. 11, 457-465 (1997).	
<del> </del>		KERR, J. S., et al., "Novel Small Molecule αν Integrin Antagonists: Comparative Anti-Cancer	
		Efficacy with Known Angiogenesis Inhibitors," <i>Anticancer Research</i> , 19:959-968 (1999).	
<del></del>		LAUE, T. M., et al., Methods in Enzymology, 182:566-587 (1990).	
$\vdash$			<del> </del>
	ŀ	PASSANITI, A., et al., "Methods in Laboratory Investigation: A Simple, Quantitative Method for	
		Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement	
1 1		Membrane, Heparin, and Fibroplast Growth Factor," <i>Laboratory Investigation</i> , 67:4, 519-528	
$\vdash \vdash$		(1992).	<u> </u>
		PLUDA, J. M., "Tumor-Associated Angiogenesis: Mechanisms, Clinical Impliations, and	
		Therapeutic Strategies," Seminars in Oncology, 24:2,202-218 (1997).	
1	$\setminus$	RAJU, K. S., et al., "Characterization of a chemoattractant for endothelium induced by	
	<u>1                                    </u>	angiogenesis effectors," Cancer Res., 44(4):1579-84 (1984).	ļ
火	$(\mathcal{M})$	RAK, J., et al., "Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls,"	
		Cancer and Metastasis Reviews 15:231-236 (1996).	<u> </u>

Examiner Signature	INTE	Date Considered	9/22	103
			7 /	

Form PTO/SB/08B				Complete if Known		
				Application Number	Not Yet Assigned	
		N DISCL		Filing Date	Herewith	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Éric DUPONT et al.	
,	(use as many sheets as necessary)			Group Art Unit	Not Yet Assigned	
(use a				Examiner Name	Not Yet Assigned	
Sheet	5	of	6	Attorney Docket Number	014985-6U1	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book,	T <sub>1</sub>
Initials	magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a	
	book, also include publisher and city and/or county where published.  SAUDER, D. N., et al., "Angiogenesis in Dermatology," Curr Prob Dermacol, 1-10 (2001).	
17W	SIEMEISTER, G., et al., "Two Independent Mechanisms Essential for Tumor Angiogenesis:	
<i>LL</i>   \	Inhibition of Human Melanoma Xenograft Growth by Interfering with either the Vascular	l
(SAM)	Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," <i>Cancer Research</i> 59,	1
1/19	3185-3191 (1999).	
<del>                                     </del>	TAKANO, S., et al., "Concentration of Vascular Endothelial Growth Factor in the Serum and	
I	Tumor Tissue of Brain Tumor Patients," <i>Cancer Research</i> 56, 2185-2190 (1996).	
	WEBER, G., "Biochemical Strategy of Cancer Cells and the Design of Chemotherapy: G.H.A.	
1 1	Clowes Memorial Lecture," <i>Cancer Research</i> , 43:3466-3492 (1983).	
	OIKAWA, T., et al., "A novel angiogenic inhibitor derived from Japanese shark cartilage (I).	+
	Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis,"	
	Cancer Letters, 51 pp. 181-186 (1990).	
	MOSES, M., et al., "Inhibitors of Angiogenesis," Biotech 9:630-634 (1991).	-
	HORSMAN, et al., Acta Oncologica (Stockholm) 37(5):441-445 (1998) (Abstract).	+
	MILLER, et al., Journal of Clinical Oncology 16(11):3649-3655 (1989) (Abstract).	- <del></del>
<u> </u>	AUERBACH, W., et al., Pharmac. Ther. 63:265-311 (1994)	<u> </u>
		<del></del>
	BISCHOFF, J., <i>Trend Cell Biol.</i> , 5:69-74 (1995)	-
	BROOKS, P.C., Cancer Metastasis Rev., 15:187-194 (1996)	-
	BROOKS, P.C., <i>Eur. J. Cancer</i> , 32A:2423-9 (1996)	-
	BUSSOLINO, F., et al., Eur. J. Cancer, 32A:2401-12 (1996)	-
	FERRARA, N., Nature, 376-467 (1995)	
	FERRARA, N., et al., Endocrine Rev., 18:4-25 (1997)	
	FORM, D., et al., J. Cell Physiol., 152:196-205 (1992)	
	HAMADA, J., et al., Br. J. Cancer, 66:349-354 (1992)	
	HANSON, et al., J. Bone & Min. Res., 7:1251-1258 (1992)	
	INGBER, Sem. Cancer Biol., 3:57-63 (1992)	
	JAFFE, et al., J. of Clin. Invest., 52:2745-2756 (1973)	
	KLAGSBRUN, M., et al., Annu. Rev. Physiol., 53:217-32 (1991)	
	KLEIN, S., et al., Mol. Biol. Cell., 4:973-82 (1993)	
	KLEIN, S., et al., J. Biol. Chem., 271:22583-90 (1996)	
	KNIGHT, et al., FEBS Let., 296, 263-266 (1992)	
	KNIGHTON, D.R., et al., Science, 221:1283-85 (1983)	
	KOCH, A.E., et al., Nature, 376:517-19 (1995)	$\perp$
	LAEMMLI, U.K., <i>Nature</i> , 227:680 (1970)	
	MAZURE, N.M., et al., Cancer Res., 56:3436-40 (1996)	
	MIGNATTI, P., et al., J. Cell. Biol., 113:1193-201 (1994)	
	MOSES, M.A., et al., Int. Rev. Cytol., 161:1-48 (1995)	
	PEPPER, M.S., et al., J. Cell Physiol., 152:196-205 (1992)	
	PEPPER, M.S., et al., Biochem. Biophys. Res. Commun., 189:824-31 (1992)	
0 A	POLVERINI, P.J., <i>Eur. J. Cancer</i> , 32A:2430-7 (1996)	
	PROOST, P., et al., Int. J. Clin. Lab. Res., 26:211-23 (1996)	

Examiner Signature	MIR	Date Considered 9/22/03

Form PTO/SB/08B					Complete if Known	
				Application Numb r	Not Yet Assigned	
	MATION			Filing Date	Herewith	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Éric DUPONT et al.	
			/	Group Art Unit	Not Yet Assigned	
(use a	s many she	eus as nec	cessary)	Examiner Name	Not Yet Assigned	
Sheet	6	of	6	Attorney Docket Number	014985-6U1	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	-
Exr	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book,	T <sub>1</sub>
Initials >	magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a	
	book, also include publisher and city and/or county where published.	
=100	RAK, J., et al., Eur. J. Cancer, 32A:2438-50 (1996)	
	RAK, J., et al., J. Cell. Physiol., 159:245-55 (1994)	1
$\vdash \cup \vdash \vdash$	ROSEN, et al., Medical Hypotheses, 6:441-446 (1980)	1
<del></del>	SANDER, P., et al., Kidney Int., 51:448-53 (1997)	+
<del> </del>	GRUDEL, F., et al., Numey Int., 91.440-00 (1997)	+
ļ	SCHWARTZ, S.M., et al., J. Cardovasc. Pharmacol., 21 sUPPL. 1:S31-S49 (1993)	
L	SCHWEIGERER, L., et al., Nature, 325:258-9 (1987)	_
	WELGUS, et al., J. Biol. Chem., 256:9511-9516 (1979)	
	WILKIN, J.K., Arch. Dermatol., Vol. 130, 359-362 (1994)	
1 //		
		<del> </del>
		<b>_</b>
		1
		-
		<del></del>
		<del>- </del> -
		-
		1
. — —		+
		+
		1
		+
		+

Examiner	1, DT2	Date 9/2-	/0 -
Signature	$\omega_{1/2}$	Considered   // 22	105